MedPath

to compare dexmedetomidine versus nitroglycerine as a hypotensive agent causing less blood loss in posterior fixation surgery of spine.

Not Applicable
Recruiting
Conditions
age 18-65yrs ,ASA I and II
Registration Number
CTRI/2018/04/013065
Lead Sponsor
Vardhaman Mahavir Medical College And Safdarjung Hospital
Brief Summary

Thisstudy is planned to compare dexmedetomidine with nitroglycerine as a hypotensiveagent during posterior fixation surgery of spine in terms of

(1)intraoperative haemodynamic changes and blood loss

(2)the recovery characteristics and side effects .

HYPOTHESIS-Dexmedetomidineis superior than nitroglycerine as a hypotensive agent in patients undergoingposterior fixation surgery of spine.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
40
Inclusion Criteria

1.Patients of age 18-65yrs undergoing posterior fixation of spine surgery under general anaesthesia 2.ASA I and II.

Exclusion Criteria

1.Patients with hypertension 2.Patients with history of significant systemic disorders ( like cardiovascular, respiratory , central nervous system, hepatic and renal ) 3.Patients with bleeding disorders.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare intra-operative haemodynamic changes and blood loss with infusion of dexmedetomidine and nitroglycerine in patients undergoing posterior fixation surgery of spine.intra-operative
Secondary Outcome Measures
NameTimeMethod
To compare the recovery characteristics and side effects of both these drugs in patients undergoing posterior fixation surgery of spine.intra-operative

Trial Locations

Locations (1)

vmmc and safdurjung hospital,new delhi

🇮🇳

South, DELHI, India

vmmc and safdurjung hospital,new delhi
🇮🇳South, DELHI, India
CHANDRIKA PRIYADARSHINI
Principal investigator
8882123216
mary.chandrika@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.